
FLEXIBLE STRENGTH. PROVEN SUCCESS.

Demonstrated long-term durable clinical outcomes in complex aortoiliac occlusive disease (AIOD) treatment through **five years.**

Sustained clinical effectiveness through five years:

- 89.5% primary patency and 96.1% primary assisted patency per lesion¹
- 89.1% freedom from target lesion revascularization (fTLR) per subject¹

This physician-initiated study enrolled 59 patients from three participating centers with patients followed out to **five years** and beyond.



Kaplan Meier graph of primary patency with number of lesions at risk



DURABLE PATIENT BENEFIT VERSUS BASELINE BEYOND FIVE YEARS¹

of patients improved ≥ 1
Rutherford category from baseline¹

improvement in mean resting ankle-brachial index (ARI) (P < 001 07

3x improvement in median WIQ measures sustained beyond five years in long-term follow-up cohort¹


	Pre-procedure	3 years	5 years†
Walking distance	7 (N = 59)	25 (N = 39)	21 (N = 27)
Walking speed	3 (N = 59)	10 (N = 39)	9 (N = 27)
Stair climbing	3 (N = 50)	11 (N = 38)	9 (N = 27)

^{* (}P < .001) Statistically significant change from pre-procedure.



Reference

1. Holden A, Takele E, Hill A, et al. Long-term follow-up of subjects with aortoiliac occlusive disease treated with the VIABAHN VBX balloon expandable endoprosthesis. Presented at Cardiovascular & Interventional Radiological Society of Europe (CIRSE) 2022; September 10-14, 2022; Barcelona, Spain. CardioVascular & Interventional Radiology 2022;45:Supplement:S147. Abstract 301.1.



eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5 mm-13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation. CONTRAINDICATIONS: Do not use the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only

Products listed may not be available in all markets.

GORE, Together, improving life, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2022 W. L. Gore & Associates, Inc. 22638700-EN SEPTEMBER 2022



[†] Median follow-up of 6.6 years.